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Abstract 
The generation of 3-nitrotyrosine, within proteins, is a post-translational modification 
resulting from oxidative or nitrative stress. It has been suggested that this modification 
could be used as a biomarker for inflammatory diseases. Despite the superiority of 
mass spectrometry-based determinations of nitrotyrosine, in a high-throughput clinical 
setting the measurement of nitrotyrosine by an enzyme-linked immunosorbent assay 
(ELISA) is likely to be more cost-effective. ELISAs offer an alternative means to detect 
nitrotyrosine, but many commercially available ELISAs are insufficiently sensitive to 
detect nitrotyrosine in healthy human serum. Here, we report the development, 
validation and clinical application of a novel electrochemiluminescence-based ELISA for 
nitrotyrosine which provides superior sensitivity (e.g. a 50-fold increase in sensitivity 
compared with one of the tested commercial colorimetric ELISAs). This nitrotyrosine 
ELISA has the following characteristics: a lower limit of quantitation of 0.04 nM nitrated 
albumin equivalents; intra- and inter-assay coefficients of variation of 6.5% and 11.3%, 
respectively; a mean recovery of 106 ± 3% and a mean linearity of 0.998 ± 0.001. Far 
higher nitration levels were measured in normal human blood cell populations when 
compared to plasma. Mass spectrometry was used to validate the new ELISA method. 
The analysis of the same set of chemically modified albumin samples using the ELISA 
method and mass spectrometry showed good agreement for the relative levels of 
nitration present in each sample. The assay was applied to serum samples from 
patients undergoing elective surgery which induces the human inflammatory response. 
Matched samples were collected before and one day after surgery. An increase in 
nitration was detected following surgery (median (IQR): 0.59 (0.00-1.34) and 0.97 (0.00-
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1.70) nitrotyrosine (fmol of nitrated albumin equivalents/mg protein) for pre- and post-
surgery respectively. The reported assay is suitable for nitrotyrosine determination in 
patient serum samples, and may also be applicable as a means to determine oxidative 
stress in primary and cultured cell populations. 
Graphical abstract 
Keywords: 3-nitrotyrosine, oxidative stress, nitrative stress, peroxynitrite, inflammation, 
human serum, enzyme-linked immunosorbent assay, mass spectrometry 
Highlights: 
 A highly sensitive ELISA for measurement of 3-nitrotyrosine has been developed 
 The new ELISA was validated by mass spectrometry 
 Nitration levels in human blood cell populations were higher than in plasma 
 An increase in serum nitration after surgery was observed in patients  
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Abbreviations: Electrochemiluminescence (ECL), Meso Scale Discovery (MSD), 
nitrated BSA (BSA-NO2) and lower limit of quantification (LLOQ). 
 
Introduction 
Tyrosine nitration is the replacement of the C3 hydrogen atom, on the aromatic ring of 
tyrosine, with a nitro group [1], forming 3-nitrotyrosine. This modification is considered to 
result from oxidative stress and occurs with both free tyrosine (to generate free 
nitrotyrosine) and tyrosine within a polypeptide sequence (to produce the protein 
residue adduct, nitrotyrosine). There are several pathways leading to nitration in 
biological systems, but reactive oxygen species (ROS) are invariably involved and many 
of the described pathways involve a two-step process [2] containing, first, the formation 
of a tyrosine radical and, secondly, the reaction of the tyrosine radical with the free 
radical nitrogen dioxide (•NO2).  
The formation of nitrotyrosine in human tissues/bio-fluids is associated with a number of 
human diseases which involve a strong inflammatory component. In inflammatory 
environments, two key nitrating entities, peroxynitrite [3, 4] and the myeloperoxidase-
H2O2-NO2
¯ system [5, 6], are both induced. This suggests that nitrotyrosine could be 
measured as a marker of oxidative stress in clinical studies. For example, plasma 
protein-associated nitrotyrosine concentrations are increased in patients with systemic 
lupus erythematosus [7], celiac disease [8], rheumatoid arthritis [9] and cardiovascular 
disease [10, 11], when compared to healthy control individuals. Increased levels of 
nitrotyrosine have also been observed in aortic ring tissue from rats following 
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pharmacological treatment [12] and in mouse plasma after exposure to stressful 
environmental conditions, such as traffic noise [13].  
Some studies have shown that plasma nitrotyrosine levels correlate with disease activity 
[14-16] and decrease following drug therapy (e.g. statin and rosuvastatin for 
cardiovascular conditions) [10, 17]. However, the current evidence that oxidative protein 
modifications are useful biomarkers of disease is compromised by the use of poorly 
validated methods and the limited number of large clinical studies. The nitrotyrosine 
modification is no exception to these problems [18]. When measuring nitrotyrosine there 
are two major methodological issues to consider: (1) low concentrations of the analyte 
and (2) artefactual formation of nitrotyrosine during sample processing [19]. There have 
been two main approaches to quantifying nitrotyrosine levels in human plasma and 
other bio-fluids: ELISAs and GC/LC-MS/MS. These methods have both advantages and 
disadvantages. The existing ELISA methods for nitrotyrosine are high throughput, 
relatively cheap and do not involve extensive sample preparation, but they have low 
sensitivity and are often semi-quantitative. Issues of specificity must also be considered 
as antibodies might cross-react with other oxidative modifications present, such as 
chlorotyrosine or nitrophenylalanine [20, 21]. GC/LC-MS/MS is quantitative, highly 
sensitive and accurate but is low-throughput, time consuming and expensive, limiting 
this method’s usefulness in a clinical setting. The risk of nitrotyrosine formation during 
sample derivatization for gas chromatography is also a potential confounding factor [22, 
23]. 
For the measurement of nitrotyrosine in a large number of clinical samples, the high-
throughput capacity of an ELISA is preferable. Nonetheless, limitations with existing 
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nitrotyrosine ELISAs need to be addressed before an ELISA can be recommended as a 
prognostic tool in a clinical setting. Although earlier studies have reported the 
development of ELISAs for nitrotyrosine [8, 24, 25] and commercial nitrotyrosine assays 
are widely available and have limits of detection in the range of 1-2 nM, an obstacle still 
to be addressed is poor sensitivity of these assays. Indeed, existing ELISA methods are 
often unable to detect nitrotyrosine in a high proportion of human serum samples. 
Therefore a high-throughput assay based on a highly sensitive 
electrochemiluminescence (ECL) platform was developed for nitrotyrosine 
measurement. The ECL method uses an electrical current to produce light. The base of 
the ELISA plate contains carbon electrodes which transmit the electrical current to the 
antibody/antigen complex. The streptavidin tag is conjugated to a ruthenium complex 
which undergoes redox cycling, following electrical stimulation, resulting in the 
production of light. Due to the low background and amplification of light signals, through 
excitation cycles, this platform is highly sensitive [26].  
Here we report a novel ELISA for nitrotyrosine which has been analytically validated by 
LC-MS/MS. We used the assay to compare nitrotyrosine concentrations in normal 
human plasma, isolated blood cells and cultured cells. We have also applied the assay 
to serum samples from patients undergoing major elective surgery (as an exemplar of 
the acute inflammatory response in humans).  
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Materials and Methods 
Reagents  
Ultra-pure water was used for buffer preparations throughout. The following reagents 
were from Sigma Aldrich (Gillingham, UK): phosphate buffered saline powder (PBS; 
product number P5368), bovine serum albumin (BSA; fraction V, ≥96% pure), 
acetonitrile (anhydrous, 99.8%), iodoacetamide (BioUltra), trypsin (proteomics grade), 
radioimmunoprecipitation assay (RIPA) buffer, protease inhibitor cocktail (product 
number P8340: pre-made solution of 4-(2-aminomethyl) benzenesulfonyl fluoride 
hydrochloride at 104 mM, aprotinin at 80 μM, bestatin at 4 mM, E-64 at 1.4 mM, 
leupeptin at 2 mM and pepstatin A at 1.5 mM) and Percoll (lot 10226958). 
Nitrated bovine serum albumin (nitrated BSA, prepared using tetranitromethane as a 
nitrating reagent), was purchased from Enzo Life Sciences (New York, USA). Dextran, 
batch DB4311, was from Pharmacosmos, Holbæk, Denmark. Methanol (analytical 
reagent grade), acetic acid (1M solution), ammonium bicarbonate (analytical reagent 
grade), dithiothreitol (product number P2325, 1 M aqueous solution), formic acid (LC-
MS grade), Tween-20, foetal bovine serum (FBS, lot 41F6547K) and HyClone™ 
antibiotic-antimycotic solution (lot J140011) were supplied by Fisher Scientific, 
Loughborough, UK. Pierce protein-free blocking buffer, in PBS, was purchased from 
Thermo Scientific (Cramlington, UK). Dulbecco's modified Eagle's medium (DMEM), 
high glucose DMEM, and L-glutamine were supplied by Lonza (Wolverhampton, UK). 
Coomassie brilliant blue was purchased from LKB Produkter (Stockholm, Sweden). 
Acetonitrile (HiPerSolv Chromanorm UPLC grade) was from VWR (West Sussex, UK). 
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The primary antibody (monoclonal mouse anti-nitrotyrosine, clone number 
CC.22.8C7.3) and secondary antibody (biotinylated monoclonal mouse anti-
nitrotyrosine, clone number CC.22.8C7.3) were from Cambridge Biosciences 
(Cambridge, UK). “Blocker A” (product number R93BA-4), SULFO-TAG labelled 
streptavidin and “Read Buffer T 4x” were purchased from Meso Scale Discovery (MSD), 
Maryland, USA. 
Human peripheral blood samples 
The nitrotyrosine assay was applied to healthy human plasma and isolated human 
blood cells. The volunteer blood donors gave informed consent, and this study was 
approved by the Institutional Research Ethics Committee - approval number 2014/781. 
For the separation of cells from normal human peripheral blood, the following protocol 
was used as previously described [27]. The whole blood (approx. 5 ml) was collected 
into EDTA tubes and centrifuged for 20 min at 350 g, and the plasma was removed. 
Red blood cell sedimentation was achieved by incubating the cells with dextran (6% 
w/v), for 30 min at room temperature. The peripheral blood mononuclear cells were 
isolated using a discontinuous Percoll gradient [27]. Centrifugation through the gradient 
(20 min, 720 g, 4°C) resulted in mononuclear cells being retained at the upper boundary 
(between the 68 and 55% Percoll). 
In order to study the effect of the surgery-induced inflammatory response on 
nitrotyrosine levels, serum was collected from 35 patients (18 male, 17 female; 59 ± 13 
years old) prior to major elective surgery and again 24 hours after surgery. Clotted 
blood samples were collected from each patient, at each of the two time points, and 
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stored frozen in a study approved by the National Research Ethics Service Committee 
South Central (Research Ethics Committees ref 06/Q1702/152). Prior informed consent 
to take part in the study was obtained from each individual. The types of major elective 
surgery undertaken were as follows: resection (thyroid, bowel, colon, stomach, gall 
bladder or liver – 10 patients), hernia repair (5 patients), kidney, gall or bladder stone 
removal (5 patients), unknown (5 patients), removal of bladder/urinary diversion (4 
patients), treatment of fistulas (3 patients), tumour removal (1 patient), laparoscopic 
examination of abdominal cancer (1 patient) and treatment of severe claudication (1 
patient). C-reactive protein (CRP) was measured at the Clinical Chemistry department, 
Royal Devon and Exeter (RD&E) Hospital, using an immunoturbidimetric assay based 
on the analytical platform of a Roche Cobas automated analyser (Roche Dianostics, 
West Sussex UK). The CRP assay had a range of 0.3-350 mg/L. Clinical information 
including white blood cell count (counts for each cell type), blood creatinine and blood 
urea, was available for some of the patients (n=26 pre-surgery and n=16 post-surgery; 
14 matched pairs). 
Cell culture 
Human U937 cells (a histiocytic lymphoma cell line) were obtained from the ECACC 
(European Collection of Authenticated Cell Cultures) via Sigma-Aldrich (Gillingham, UK, 
lot 11D008). U937 cells [28] were cultured in DMEM supplemented with 10% foetal 
bovine serum, 4 mM L-glutamine and an antibiotic/antimycotic solution (100 units/ml of 
penicillin, 100 µg/ml of streptomycin and 0.25 µg/ml of amphotericin B). These non-
adherent cells were pelleted by centrifugation at 450 g for 5 min. The media was then 
removed and the cells were washed twice with PBS (450 g for 5 min). 
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New electrochemiluminescence-based ELISA method 
Preparation of standards: nitrated BSA was aliquoted into 1 µM stock solutions 
(reconstituted with distilled water) prior to use. The PBS solution contained 10 mM 
phosphate, 138 mM NaCl and 2.7 mM KCl (pH 7.4). A 1 µM stock was then diluted with 
dilution buffer (1% Blocker A in PBS) to a concentration of 10 nM to form the highest 
data point of the standard curve (standard range 0.04 nM–10 nM). 
Preparation of plasma, serum and isolated cell samples: Immediately prior to use, 
plasma/serum samples were defrosted and kept on ice. The plasma/serum was diluted 
1 in 5 with dilution buffer (1% Blocker A in PBS) immediately prior to use. All cells were 
lysed in order to measure cellular protein nitration. Human red blood cells were lysed by 
hypotonic lysis. Human peripheral blood mononuclear cells and U937 cells were lysed 
using RIPA buffer with a protease inhibitor cocktail, according to the manufacturer’s 
instructions.  
Electrochemiluminescence-based sandwich ELISA protocol: “Standard bind” single spot 
96-well plates were purchased from MSD  (Maryland, USA) and the platform for 
analysis of the plates was an ECL Sector Imager 2400 (MSD, Maryland, USA). Primary 
antibody (non-biotinylated, diluted in PBS to 1 µg/ml) was pipetted into each well of the 
plate and then incubated at 4°C overnight. The plate was then blocked with 150 µl 
blocking buffer (3% Blocker A in PBS), at 25°C for one hour with gentle agitation (Jeio 
Tech Lab Companion SI-300R shaking incubator, Meadowrose Scientific Limited West 
Sussex, UK). The plate was then washed three times with wash buffer (0.05% Tween-
20 in PBS). Each standard/sample (25 µl) was added to the relevant well, with 
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quadruplicate repeats of each, and incubated for another hour. The plate was washed 
as above. Each well was incubated with the biotinylated secondary antibody (2 µg/ml in 
dilution buffer) followed by another wash step and incubation with the streptavidin tag 
for an hour (1:500 in dilution buffer; streptavadin-coupled to a ruthenium complex). After 
a final wash, the Read Buffer (150 µl, 2x concentration obtained by dilution with dH2O) 
was placed into each well and the plate immediately read on the MSD Sector Imager 
2400. The standard curve was plotted and the sample concentrations calculated from 
these known values. The results were expressed using the unit “nitrated BSA 
equivalents”, which represents the protein concentration of the commercial nitrated BSA 
sample which produced an ECL signal equivalent to that of the unknown sample.  
Validation of the new ECL-based ELISA 
Lower limit of quantification and co-efficient of variation: The lower limit of quantification 
(LLOQ) was defined using the US Food and Drug Administration definition of: the lowest 
standard with a mean accuracy of 80-120% and a duplicate variation of <20% [29]. The 
coefficient of variation (CV) was determined by preparing and measuring the same 
sample multiple times within and across plates (n=8). CV% = (standard deviation/mean) 
x 100%. The inter-assay CV for room temperature incubations compared to incubations 
at a constant temperature of 25°C was also assessed. 
Recovery and linearity: A plasma sample was spiked with 1 nM of commercially nitrated 
BSA (nitrated BSA; Enzo Life Sciences) and diluted to four different concentrations (1 in 
2, 1 in 5, 1 in 10 and 1 in 20) to determine the linearity and recovery of the assay. 
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Antibody specificity: Control experiments were performed, involving both pre-incubation 
(up to 1 hour) of the detection antibody with 120 µM free 3-nitrotyrosine, and spiking of 
a nitrated BSA sample with 120 µM free 3-nitrotyrosine. The antibody has been 
previously characterised in relation to affinity and cross-reactivity [21, 30]. The antibody 
was reported to have the following cross-reactivities with amino acids similar to 3-
nitrotyrosine: 4-nitrophenylalanine: 0.1%; L-tyrosine: 6.2%; 3,5-dinitrotyrosine 1.2% [21]. 
The manufacturer (Cayman Chemical) states a cross-reactivity with chlorotyrosine of 
<5%. 
Validation of the ECL-based ELISA by mass spectrometry: In order to prepare 
chemically modified BSA samples, BSA (15 µM) in a bicarbonate buffer (25 mM 
NaHCO3 and 100 mM KH2PO4) was exposed to 3, 1.5. 0.75 and 0.3 mM peroxynitrite 
(synthesized according to the method described in reference [31]) to cause nitration of 
tyrosine residues. A 1 mL sample of the BSA, which had been exposed to 3 mM 
peroxynitrite, was diluted with 800 µL PBS. This sample was then mixed with sodium 
dithionite (200 µL of 1.4 M stock solution; final concentration 140 mM), added as 10 µL 
drops every 2 min, whilst being stirred on ice (final BSA concentration 7.5 µM). The 
solution was incubated on ice (with stirring) for a further 30 min, to chemically reduce 
the nitro groups to amino groups [25]. The solution was then transferred into an 
Eppendorf tube and centrifuged for 5 min (14,000 g, 2 °C). The supernatant was 
collected into a pre-cooled tube and stored at -20°C until use. 
In preparation for mass spectrometry, native (unmodified), nitrated (by peroxynitrite) and 
chemically reduced BSA samples were run on an SDS-PAGE, and the bands excised 
and digested with trypsin as previously described  [32]. Peptides were separated on an 
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Ultimate 3000 high-pressure liquid chromatography system (Dionex, UK) coupled to a 
5600 Triple TOF mass spectrometer (Sciex, Warrington UK). The peptides were 
separated on a nano-HPLC column (0.075 x 150 mm 3 µm PepMap C18, Thermo 
Scientific, Hemel Hempstead, UK) at a flow rate of 300 nL/min using a gradient elution 
running from 2% - 45% aqueous acetonitrile (0.1% formic acid) over 60 min. Ionisation 
of the peptides was achieved with the following settings: spray voltage 2.4 KV, source 
temperature 150ºC, declustering potential 50 V and a curtain gas 15. High resolution 
TOF MS mode was used to collect survey scans in positive mode from 400 to 1200 Da 
for 200 ms. MS/MS data was collected using information-dependent acquisition with the 
following criteria: the 10 most intense ions with +2 to +5 charge states and a minimum 
intensity of 500 counts-per-second was chosen for analysis, using dynamic exclusion 
for 20 s, 250 ms acquisition time, and standard settings for rolling collision energy. 
The generated data were analyzed using Mascot Daemon statistical software v 2.3.2 
(Matrix Science, London, UK [33]) with the following search parameters: type of search: 
MS/MS Ion Search; enzyme: trypsin; variable modifications: carbamidomethyl (C), 
oxidation (M), nitro (Y) and nitro (W); mass values: monoisotopic; protein mass: 
unrestricted; peptide mass tolerance ± 0.1 Da; fragment mass tolerance: ± 0.1 Da; max 
missed cleavages: 2; instrument type: ESI QUAD TOF. Additional searches were 
performed with amino (Y) or oxidation (C) as variable modifications, in place of nitro 
(W). Matches for bovine albumin were then examined for the listed modifications.  
The relative amounts of the nitrated peptides were calculated using the Peak View 
software (AB SCIEX Version 2.0 [34]). Peptide extracted ion chromatograms (XIC), 
were generated at the m/z of the peptides containing either one/two unmodified 
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tyrosines, or one/two nitrated tyrosines, or one unmodified tyrosine within a peptide 
which also contained one nitrated tyrosine, where these modification were identified in 
the Mascot search (width 0.1 Da). One observed peptide sequence 
(RHPYFYAPELLYYANK) – in both its unmodified and various nitrated forms - was 
excluded from the data analysis, due to more than one XIC peak being generated for 
the m/z values of nitration at multiple tyrosine residues. With this single exception, there 
were no detected peptides containing more than two unmodified tyrosines or more than 
two nitrated tyrosines. The XIC peak area of each peptide that contained one or two 
nitrotyrosine residues was divided by the total peak area of the nitrotyrosine containing 
peptide(s) and the corresponding unmodified peptide to give the relative percentage 
modification. The above analysis of the data is based on the assumption that the 
modified and corresponding unmodified peptide behaved similarly in the MS analysis, 
for example in terms of ionization efficiency and detector sensitivity. Therefore, the 
calculated ratio of modified to unmodified forms for each peptide was an approximation 
[35]. Peaks with areas below 1.0 x 104 were excluded and the peak areas for the 
remaining peaks were recorded.  
The Enzo nitrated BSA standard was also analyzed by the same method.  The locations 
of nitrated tyrosine residues were confirmed by de novo sequencing using the Peak 
View software (AB SCIEX Version 1.0 [34]). A 3D ribbon cartoon indicating the locations 
of modified residues was generated using PyMol Molecular Graphics System 
(Schrödinger LLC). 
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Determination of protein concentration and protein carbonyls 
The protein concentration was determined by the bicinchoninic acid (BCA) assay [36] 
(Thermo Scientific Cramlington, UK), and the protein carbonyl content was measured 
using a commercial EIA kit (BioCell Corporation Ltd, NZ).  
Statistical analysis 
Data sets were tested for a normal distribution using the Shapiro-Wilk’s test and the 
appropriate parametric (two-way ANOVA) or non-parametric (Wilcoxon matched pairs 
and Kruskal-Wallis) tests were selected accordingly. 
 
 
Results  
Assay characteristics  
The new ECL-based ELISA, described here, provides approximately fifty times more 
sensitivity than a colorimetric ELISA (Figure 1). The LLOQ was determined to be 0.04 
nM nitrated BSA. Plasma was spiked with 1 nM nitrated BSA and diluted to 4 different 
concentrations for determination of linearity and recovery. The average linearity and 
recovery were 0.998±0.001 (n=3) and 107±3% (n=4) respectively (the full source data 
sets are reported in the Supplementary Material, Tables S1 and S2 respectively). A 1 in 
5 dilution was selected for the analysis of serum samples as a balance between 
maximising the signal in samples which contained low concentrations of nitrotyrosine 
whilst only needing a low volume of sample. 
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Figure 1: A comparison of typical standard curves generated by the 
electrochemiluminescence (ECL)-based ELISA and a commercially-available 
colorimetric ELISA. The limit of detection of the ECL ELISA (squares) was lower 
than that of the colorimetric ELISA (circles). Abbreviations, R.L.U., relative light 
units. BSA-NO2, nitrated BSA. 
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The inter-assay coefficient of variation (CV) was determined using a control plasma 
sample containing a mean concentration of 2.4 nM nitrotyrosine (nitrated BSA 
equivalents), giving a CV of 11.3% (n=8). This CV was obtained under conditions where 
the assay plate was maintained under a constant temperature of 25°C, using a plate 
incubator (see ‘Materials and Methods’). Recovery determinations were performed 
under conditions of either a constant temperature of 25°C, or at room temperature 
(without the use of the plate incubator): when four plasma samples were spiked with 10 
nM nitrated BSA, the recovery of the spiked standard (mean and standard deviation 
(SD)) was 8.4 ± 5.4 and 8.3 ±1.4 nM nitrotyrosine (nitrated BSA equivalents) for room 
temperature and 25°C, respectively. The smaller SD of the assay at a fixed 25°C 
indicates that this assay procedure was superior to relying on room temperature 
conditions. 
Pre-incubation of the secondary antibody with free nitrotyrosine caused a decrease in 
the ELISA chemiluminescence signal compared with the signal generated in the 
absence of free nitrotyrosine (p=0.03, Kruskal-Wallis test, n=3). However, when free 3-
nitrotyrosine was incubated with the nitrated BSA sample (i.e. free 3-nitrotyrosine and 3-
nitrotyrosine residues within BSA were competing for antibody binding) there was no 
decrease in the signal, despite the concentration of free nitrotyrosine being in excess of 
the protein associated nitrotyrosine (free nitrotyrosine would be expected to inhibit the 
assay signal due to the ‘sandwich’ design needing two epitopes), suggesting that the 
antibody has a higher affinity for the protein associated nitrotyrosine.  
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The commercial nitrated BSA standard (Enzo Life Sciences) was analyzed by mass 
spectrometry and the three confirmed nitrotyrosine residues identified are highlighted in 
Figure 2.  
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Figure 2: Ribbon cartoon representing the three dimensional structure of native 
bovine serum albumin (BSA, pdb 3V03), and showing the positions of the 
nitrated tyrosine residues in the commercial BSA standard, as identified by 
mass spectrometry. Tyrosine residues (Y) confirmed to be nitrated by mass spectrometry 
(protocol described in ‘Materials and Methods’ subsection ‘Validation of the new ECL-based 
ELISA by mass spectrometry’) are highlighted in red, and sequence coverage was 65%. The 
α-helices are shown in blue and the connecting loop regions in pink. BSA contains 21 tyrosine 
residues: approximately 70% of these residues are buried and 30% exposed. Of the tyrosine 
residues highlighted above, tyrosine 355 and tyrosine 364 are both buried and tyrosine 424 is 
exposed. This figure was produced using PYMOL (Schrödinger, Inc). 
20 
 
 Validation of the ECL-based ELISA by mass spectrometry 
BSA modified with peroxynitrite showed a concentration-dependent increase in nitration 
in both the ELISA and mass spectrometry (MS) analysis. Sequences analyzed in the 
MS were: K.YLYEIAR.R, R.RHPEYAVSVLLR.L, K.YICDNQDTISSK.L, 
K.LGEYGFQNALIVR.Y, K.DAFLGSFLYEYSR.R, K.EYEATLEECCAK.D, 
K.YNGVFQECCQAEDK.G, R.MPCTEDYLSLILNR.L, R.RPCFSALTPDETYVPK.A and 
K.DDPHACYSTVFDK.L. The ELISA signal showed an approximate doubling in 
response to a doubling of peroxynitrite concentration, while the MS response showed a 
low increase in signal between 1.5 mM and 3.0 mM peroxynitrite. The ELISA signal for 
nitrotyrosine, in the modified BSA, was lowered to levels similar to that of the 
unmodified BSA when treated with sodium dithionite (Figure 3); this was also seen in 
the MS analysis. 
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Figure 3: Extent of the nitration of native bovine serum albumin and peroxynitrite-
treated bovine serum albumin, as detected by the new ECL-based ELISA in 
comparison with mass spectrometry. Chemically modified BSA (protocol described in 
Methods subsection ‘Validation of the new electrochemiluminescence-based ELISA by mass 
spectrometry’) was measured by the ECL-based ELISA (white bars) and by mass spectrometry 
(grey bars). A sample of BSA that had been modified using 3.0 mM peroxynitrite was 
additionally treated with Na2S2O4, to reduce nitro groups to amino groups, according to the 
procedure described in the Methods. This is indicated on the graph as “+ 140 mM Na2S2O4”. 
Median and interquartile ranges are shown (n=4 for each treatment). Where peptides contained 
more than one tyrosine residue, the signals for both mono- and di-nitrated peptides were used 
for calculation of the percentage modification. 
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Application of the assay to healthy human samples 
The isolated peripheral blood mononuclear cells, and cultured U937 cells, had 
nitrotyrosine levels that were significantly higher than the levels observed in the plasma 
from healthy individuals (p<0.05 and p<0.01 respectively, Kruskal-Wallis test). The red 
blood cells also had higher levels of nitrotyrosine, compared to the plasma, but this was 
not statistically significant.  
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Figure 4: Comparison of 3-nitrotyrosine levels in healthy human plasma, human blood 
cells and a human cell line. Levels of nitration were far lower in the plasma (n=15) compared to 
cellular samples. 3NT was measured as per the detailed protocol in the Methods subsection ‘ECL-
based ELISA method’. Cell lysates were collected as per the protocol detailed in the Methods (“Cell 
culture” subsection). RBC (red blood cells, n=6), MC (mononuclear cells, n=4) and U937 cells 
(histiocytic lymphoma cell line) at a normal glucose (NG; 5.6 mM, n=3) and high glucose (HG; 24 mM, 
n=3) concentration. Median (long horizontal bar) and IQR (short horizontal bar) shown. A log scale 
has been used for the y-axis. **p<0.01, ***p<0.001 (Dunn's Multiple Comparison Test).  
 
 
 
 
 
Application of the assay to pre- and post-surgery serum samples 
There were individual variations in baseline (i.e. pre-surgery) human serum protein 
concentrations. A statistically significant fall in the median serum protein concentration, 
post-surgery, was also observed (median (IQR): 82.5 (75.7-87.6) and 73.1 (60.5-79.0) 
mg/mL for pre- and post-surgery serum protein concentrations, respectively (p<0.01, 
Wilcoxon matched pairs)). In order to take into account these sample differences in 
protein concentrations, the ECL-based ELISA results for nitrotyrosine were normalized 
to the serum protein content and expressed as fmol nitrated BSA equivalents/mg 
protein. A small but statistically significant (p<0.05, Wilcoxon matched pairs) increase in 
normalized serum nitrotyrosine was seen post-surgery (Figure 5): the median (IQR) 
values were 0.59 (0-1.3) and 0.97 (0-1.7) nitrotyrosine (fmol nitrated BSA 
equivalents/mg protein) for pre- and post-surgery, respectively. 
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As expected, in this example of a tissue insult leading to an inflammatory response, the 
median serum concentration of the acute phase protein, CRP, was increased 
significantly following surgery: the median (IQR) values were: 3.5 (0.97-6.25) and 36 
(8.0-86) mg/mL before and after surgery, respectively (p<0.0001, Wilcoxon matched 
pairs). There was no correlation between serum CRP concentrations and serum 
nitrotyrosine levels. There was a negative correlation between serum protein 
concentration and CRP concentration (Spearman’s rank correlation coefficient rs=-
0.335, n=69: p=0.005). 
Median serum protein carbonyls also increased significantly following surgery: the 
median (IQR) values were 0.30 (0.16-0.41) and 0.39 (0.17-0.52) nmol/mg protein, 
before and after surgery, respectively (p<0.05, Wilcoxon matched-pairs test). However, 
serum protein carbonyl levels did not correlate significantly with nitrotyrosine levels. 
For some of the samples, clinical data were available in respect of the white blood cell 
populations in the blood (pre-surgery n=26 and post-surgery n=16: 14 matched 
samples). A significant increase was seen in the total neutrophil number following 
surgery: the median (IQR) values were, 3.73 (3.37-5.46) and 8.65 (7.40-9.94) 
neutrophils (x109/L) before and after surgery, respectively (p=0.0006, Wilcoxon 
matched-pairs test). Neutrophil number correlated positively with CRP concentration 
(Spearman’s rank correlation coefficient, rs=0.6152, n=40, p<0.0001).  
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Figure 5: Median serum protein nitration levels before hospital surgery, compared 
with the same patients after surgery. 3NT was measured using the protocol described in the 
‘Materials and Methods’ in paired patient serum samples, before and after surgery (n=35 in each 
group). Serum nitration levels increased following major elective surgery (*p=0.02, Wilcoxon 
matched pairs). The dashed line represents the lower limit of quantification (LLOQ). The box 
represents the lower and upper quartiles and the central line is the median. The whiskers show the 
maximum values.  
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Discussion 
A sensitive ECL-based ELISA was developed for the measurement of nitrotyrosine in 
bio-fluids. This assay has an improved LLOQ compared to existing colorimetric ELISAs. 
The determined LLOQ of the ECL-based ELISA was 0.04 nM nitrated BSA equivalents, 
compared with a LLOQ of about 2 nM for many commercial kits. The new assay also 
has good linearity, recovery and specificity. The improved sensitivity of the present 
assay is crucial, since healthy human plasma samples often contain nitrotyrosine 
concentrations that are below the limits of detection of some commercially available 
spectrophotometry-based ELISAs [8, 37].  A commercial nitrated BSA standard was 
used in the new ECL-based assay. In order to gain a better understanding of the 
structural nature of the commercial nitrated BSA protein (produced by exposing BSA to 
tetranitromethane), characterisation by mass spectrometry was carried out. Sequence 
coverage was 65% and three residues were confirmed by de novo sequencing, to be 
nitrated. These residues were in the peptide sequences: 347DAFLGSFLY(NO2)EYSR, 
360RHPEY(NO2)AVSVLLR and 421LGEY(NO2)GFQNALIVR, corresponding to nitrotyrosine 
residues at positions 355, 364 and 424, respectively. As the coverage did not include 
the entire polypeptide chain we cannot be sure that there was no nitration at other 
tyrosine residues. 
The sandwich ELISA design of the present ELISA necessitates that at least two 
epitopes (each containing a nitrotyrosine residue) must be present for a signal to be 
produced by the nitrated monomer of BSA. A chemically-modified form of BSA, 
analyzed here by MS, was also generated in our laboratory by treatment with 
peroxynitrite (unlike the commercial standard which was nitrated using 
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tetranitromethane) and was shown to be nitrated at the same tyrosine positions as 
found for the commercial standard above. The tyrosine residues at positions 355 and 
424 of BSA also showed a small degree of nitration in the untreated BSA, suggesting 
the possibility that these tyrosine residues are nitrated in vivo. The role of nearby 
charged amino acids in directing which tyrosine residues are nitrated in a protein has 
been previously discussed [38, 39] suggesting a nearby charge favors nitration but 
other studies [40] suggest uncharged polar residues are more favourable. Within the 
current study, all of the more highly nitrated tyrosine residues analyzed were adjacent to 
a negatively charged glutamic acid. 
The successful use of a single monoclonal anti-nitrotyrosine antibody, as both the 
primary and secondary antibody within the sandwich ELISA reported here, suggests 
that the antibody is able to bind to at least two different epitopes containing a nitrated 
tyrosine residue. As the tyrosine residues 356 and 364 are close together, the 
simultaneous binding of two IgG molecules to these two residues is unlikely, due to 
steric hindrance. It may therefore be implied that residue 424 putatively defines one of 
the binding sites for the anti-nitrotyrosine antibody. This commercial antibody, employed 
in the current study, was raised against peroxynitrite-treated keyhole limpet hemocyanin 
but the exact epitope in this protein is unknown. Although only three nitrated tyrosine 
residues (355, 364 and 424) were identified by de novo sequencing, the sequence 
coverage was limited to 65%. Therefore, it is not possible to exclude the possibility that 
other tyrosine residues were nitrated within the BSA standard and were recognized by 
the antibody. 
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Some ELISA-based studies report nitrotyrosine levels to be undetectable in healthy 
human plasma [8, 37]. However, other studies have suggested levels far higher than 
those observed in our study, even in good health (i.e. the absence of inflammation) [41, 
42]. ELISA methods utilising different antibodies may report different nitrotyrosine levels 
for the same sample set. This is due to antibody differences, such as whether the 
antibody is mono- or poly-clonal and which antigenic protein was used to raise the 
antibody. Different nitrated proteins have epitopes consisting of different amino acid 
sequences, producing varying affinities for the sequences surrounding the nitrated 
residues in the assayed bio-fluids. Some antibodies may also cross-react with other 
oxidative amino acid modifications [20, 21]. 
Despite a wealth of studies utilising ELISAs for nitrotyrosine measurement in clinical 
samples, the nitrotyrosine levels reported in the literature are hard to compare in a 
robust manner. For example, along with differences in the antibodies used, the ELISA 
design (indirect, competitive and sandwich) and the nature of the nitrotyrosine-
containing standard have also varied. The report by Ter Steege et al. [8] used nitrated 
plasma as a standard, where others have used nitrated BSA [20, 25, 42]. Additionally, 
there is ambiguity in the reported results, as nitrotyrosine levels were often reported as 
absolute concentrations when they were in fact “standard equivalent” concentrations. In 
order for an absolute nitrotyrosine concentration to be reported, an essential starting 
point would be that the exact amount of nitrated tyrosine in the protein standard must be 
known. However, often all that is reported is the protein concentration of the nitrated 
protein standard. Therefore, the reported concentrations presumably relate to the 
nitrated protein concentration, not the total nitrotyrosine content.  
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On measurement of the relative extent of nitration of native and chemically modified 
BSA, we observed that there was a good agreement between the described ECL-based 
ELISA and mass spectrometry analysis. In both methods an increasing signal was seen 
with increasing peroxynitrite exposure and a decrease following treatment with sodium 
dithionite (known to chemically reduce nitro groups to amino groups [25]). In relation to 
the ELISA signal obtained from the addition of increasing concentrations of 
peroxynitrite, up to a maximum final concentration of 3.0 mM, a doubling of peroxynitrite 
concentration corresponded roughly to a doubling of ELISA response. In contrast, the 
MS signal intensity appeared to exhibit a disproportionately lower increase in response 
to doubling peroxynitrite concentrations, from 1.5 mM to 3.0 mM. The explanation for 
this is unclear. However, it is possible that competing chemical reactions (e.g. radical-
mediated polypeptide scission) become more pronounced at higher peroxynitrite 
concentrations, thereby decreasing the yield of MS-detectable 3NT. Our MS analysis 
only included 4 modifications in order to avoid artefacts. For this reason we cannot rule 
out the possibility that the results obtained for the percentage modification, by tyrosine 
nitration, have been influenced by other unaddressed modifications, such as 
hydroxylation of tryptophan and tyrosine. Simultaneously, the ELISA signal exhibited a 
disproportionate enhancement, at higher peroxynitrite concentrations, perhaps as a 
result of protein aggregation and/or unfolding to provide additional epitopes for antibody 
binding. At intermediate treatment concentrations (0.3 mM – 1.5 mM), mass 
spectrometric analysis appeared to give higher nitrotyrosine levels than the ELISA; 
however, it has previously been reported for a synthetic peptide that the MS signal 
intensity of the nitro-peptide was approximately 2.5-fold higher than that of the native 
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peptide [43]. This would lead to an overestimation by MS of the extent of nitration, 
although the extent of such an effect is likely to be sequence-dependent. Tandem mass 
spectrometry is considered to be the ‘gold-standard’ method for measuring nitrotyrosine, 
especially free nitrotyrosine, as targeted methods such as MRM are highly accurate and 
can quantify the absolute nitrotyrosine concentration [22, 23, 44]. However, this 
accolade comes with a few important caveats when dealing with complex biological 
samples such as plasma/serum, owing to many factors that may confound analysis, and 
great variation in ratios of 3-nitrotyrosine to unmodified tyrosine has been discussed in 
the literature [44]. For the measurement of nitrated proteins via the generation of free 3-
nitrotyrosine, samples must be processed appropriately: digestion by acid hydrolysis 
can increase the risk of artificial formation of 3-nitrotyrosine (due to nitrite in the sample) 
and steps must be taken to minimize this formation [44]. Alternatively, the protease 
mixture pronase from Streptomyces griseus can be used, but it has been reported that 
the incubation times required for total digestion are protein-dependent, and may be as 
long as 3 days [45]. Mass spectrometry is also not ideally suited to the analysis of a 
large number of samples (such as in a clinical setting) as it is relatively time-consuming 
(low-throughput) and expensive. ELISA methods can address some of these issues, 
and we have shown here that the ECL-based ELISA is in good agreement with the 
mass spectrometry with regard to the direct measurement of the relative amounts of 
protein-bound nitrotyrosine in the nitrated BSA samples.  
Commercial ELISA kits, for measuring nitrotyrosine are unlikely to be sensitive enough 
to detect the low levels of nitrotyrosine present in some human serum samples, 
whereas the ECL-based ELISA offers fifty-fold greater sensitivity, allowing the detection 
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of nitrotyrosine in a greater proportion of these samples. Multiple sample types were 
assayed using this new ECL-based ELISA. These results showed that nitrotyrosine 
levels were far higher in healthy human cell-derived samples compared to the 
circulating plasma levels. The highest nitrotyrosine levels were observed in 
unstimulated U937 cells in this study. As is conventional, these cells were cultured 
under atmospheric oxygen concentrations (21% oxygen). However, the U937 cell line is 
derived from a histiocytic lymphoma. Lymphocytes circulate through the blood and 
lymphatic system and, within secondary lymph organs, the physiological oxygen 
concentration may be as low as 5% [46]. As such, the cultured cells could be 
considered to be in a state of oxidative stress [47]. This may explain the relatively high 
levels of nitrotyrosine observed in these cells. 
The ECL-based ELISA was also applied to the measurement of nitrotyrosine in serum 
from patients undergoing major elective surgery, with samples collected before and 
after the surgery. This provided paired samples prior to and following an inflammatory 
insult (as confirmed by CRP levels and neutrophil counts). A change in oxidative stress 
status was confirmed by measuring serum protein carbonyl levels. A rise in oxidative 
stress, post-surgery, has previously been linked with tissue damage and recovery time 
[48, 49]. As the reactive oxygen species which have often been implicated in 
nitrotyrosine formation (peroxynitrite) have also been implicated in ischemia-reperfusion 
injury [50], protein nitration may be an important marker of damaging ROS production 
following surgery that involves ischemia-reperfusion, which would have been the case 
for some of the surgeries performed in this study. 
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Within this study, there was a wide variation in baseline (i.e. before surgery) serum 
nitration levels, with the observed median (and IQR) values for serum nitrotyrosine 
levels in patients being 0.048 (0-0.102) nM nitrated BSA equivalents before surgery. 
The large range of values may be attributed to the range of medical conditions within 
the sample group. Possibly due to the use of fluid supplementation during surgery 
and/or recovery (although the relevant clinical information was not available to allow a 
resolution of this possibility), there was a significant (p=0.007) drop in the median serum 
protein concentration following surgery. Therefore, it was necessary for the serum 
nitrotyrosine levels to be adjusted for the serum protein concentration.  
Increased oxidative stress (and nitration) may also lead to an enhanced degradation of 
modified proteins. The 20S proteasome is largely responsible for the degradation of 
proteins which have been modified as a result of oxidative stress [51, 52] and 
peroxynitrite-modified proteins are degraded faster than unmodified proteins [53, 54]. 
When Souza et al. [54] exposed Cu-Zn superoxide dismutase to peroxynitrite, nitration 
of a single tyrosine residue was determined to be the only structural modification, and 
degradation by the proteasome was enhanced. This suggests that nitrated proteins are 
marked for degradation and therefore more likely to be removed than non-nitrated 
proteins. Such a process may partially explain why the concentrations of protein bound 
nitrotyrosine in some of the clinical samples analyzed in the present study, were very 
low. However, it should be noted that when oxidative stress becomes excessive 
proteins may cross-link and aggregate, preventing them from being degraded and may 
even bind to, and inhibit, the proteasome [52, 55]. Therefore, in diseases with excessive 
oxidative stress, the levels of protein-associated nitrotyrosine will not be affected by 
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protein degradation. However, this might affect analysis by mass spectrometry and 
recognition of nitrotyrosine by antibodies. 
Radák et al. [56] measured serum nitrotyrosine daily in people doing a super-marathon; 
this extreme exercise induces an inflammatory reaction. The authors noted an increase 
in serum nitrotyrosine, when comparing the baseline with day one of the race, but then 
the levels of nitrotyrosine plateaued, despite the increasing intensity of the race. Radák 
et al. [56] proposed that this was due to the processes of nitration and degradation 
reaching equilibrium. However, the authors did not mention measuring the protein 
concentration of the serum over the course of the race (intense exercise can cause 
proteinuria), or correction of their results for protein content. If a drop in protein 
concentration occurred, each day, then an adjustment for protein concentration would 
have shown nitration levels increasing rather than remaining constant. However, few 
published studies show nitrotyrosine results corrected for protein concentrations and 
this may account for some of the discrepancies between different studies. Weber et al. 
[25] suggested that all samples should be diluted to the same protein concentration 
prior to measurement. This was highlighted as a methodological issue (as protein 
concentration may affect assay performance) but would also act as a way of 
normalizing the results from different samples to a single protein concentration.  
Limitations 
Some limitations of this study should be noted. Firstly, a validation of the novel ELISA 
against the “gold standard” MRM-based method for analysis of free nitrotyrosine was 
not carried out on the patient samples, owing to the complexity of the sample 
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preparation for the mass spectrometry method. This would be desirable for future work 
to provide additional confirmation of the levels of nitrotyrosine in individual samples. The 
patient sample analysis was also limited by the large variety of presenting diseases in 
the studied patient population, as well as the range in the types of surgery to which the 
patients were subjected. Additionally, the numbers for any one type of surgery were too 
small to allow a statistical analysis of whether a particular surgery type was associated 
with significantly higher levels of nitrotyrosine. The blood cell populations were only 
harvested from healthy volunteers. Therefore, there is currently no information 
regarding the effects of surgery/inflammation on the levels of nitrotyrosine in different 
human blood cell types. Further studies with highly defined disease groups, but with 
large sample numbers for each group, along with the collection of both serum/plasma 
and blood cells, would address these issues. 
Although work has already been published on the low cross-reactivity of the anti-
nitrotyrosine antibody to various other nitro- compounds [30], cross-reactivity towards 
peptides or proteins containing nitrotryptophan was not tested and cross-reactivity 
cannot be ruled out.  
Conclusion 
Notwithstanding these limitations, the ECL-based ELISA described here was suitable 
for nitrotyrosine-based determination of oxidative stress in healthy human plasma, 
primary and cultured cell populations, and serum pre- and post-surgery study, and 
provides improved sensitivity as well as a robust and cost-effective method to measure 
nitrotyrosine in clinical samples. Even with the improved sensitivity of the ECL-based 
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ELISA, some patient serum samples were below the LLOQ. However, the assay still 
provided a method by which a statistically significant increase in serum nitrotyrosine 
could be detected in vivo following activation of an inflammatory response (induced by 
surgery). There is room for further improvement of the present assay, such as validation 
against MRM analysis of free nitrotyrosine and the reporting of results as an absolute 
nitrotyrosine concentration rather than as nitrated BSA equivalents. The latter is a 
weakness found in many reported ELISA results and needs to be addressed in future 
work, in order to facilitate the comparison of results from different laboratories.  
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